nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—EPHX2—Sorafenib—thyroid cancer	0.676	0.937	CbGbCtD
Fulvestrant—CYP3A4—Vandetanib—thyroid cancer	0.023	0.0319	CbGbCtD
Fulvestrant—CYP3A4—Sorafenib—thyroid cancer	0.0138	0.0192	CbGbCtD
Fulvestrant—CYP3A4—Doxorubicin—thyroid cancer	0.0084	0.0116	CbGbCtD
Fulvestrant—ESRRA—saliva-secreting gland—thyroid cancer	0.00339	0.129	CbGeAlD
Fulvestrant—Embolism venous—Sorafenib—thyroid cancer	0.00296	0.0238	CcSEcCtD
Fulvestrant—ESRRA—trachea—thyroid cancer	0.00261	0.0993	CbGeAlD
Fulvestrant—ESR2—neck—thyroid cancer	0.0026	0.099	CbGeAlD
Fulvestrant—Gastrointestinal symptom NOS—Sorafenib—thyroid cancer	0.00254	0.0204	CcSEcCtD
Fulvestrant—EPHX2—thyroid gland—thyroid cancer	0.00236	0.0897	CbGeAlD
Fulvestrant—Blood bilirubin increased—Vandetanib—thyroid cancer	0.00234	0.0188	CcSEcCtD
Fulvestrant—ESRRA—thyroid gland—thyroid cancer	0.00207	0.0785	CbGeAlD
Fulvestrant—Injection site haemorrhage—Epirubicin—thyroid cancer	0.00205	0.0165	CcSEcCtD
Fulvestrant—Injection site haemorrhage—Doxorubicin—thyroid cancer	0.0019	0.0152	CcSEcCtD
Fulvestrant—Venous thromboembolism—Epirubicin—thyroid cancer	0.00188	0.0151	CcSEcCtD
Fulvestrant—ESRRA—head—thyroid cancer	0.00183	0.0697	CbGeAlD
Fulvestrant—ESR1—neck—thyroid cancer	0.00178	0.0678	CbGeAlD
Fulvestrant—Venous thromboembolism—Doxorubicin—thyroid cancer	0.00174	0.014	CcSEcCtD
Fulvestrant—NR1H4—lymph node—thyroid cancer	0.00168	0.0637	CbGeAlD
Fulvestrant—Blood bilirubin increased—Sorafenib—thyroid cancer	0.00158	0.0127	CcSEcCtD
Fulvestrant—ESR1—Nuclear Receptors—THRB—thyroid cancer	0.00147	0.0114	CbGpPWpGaD
Fulvestrant—ESRRA—Mitochondrial biogenesis—RXRA—thyroid cancer	0.00147	0.0114	CbGpPWpGaD
Fulvestrant—EPHX2—lymph node—thyroid cancer	0.00147	0.0557	CbGeAlD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—CITED1—thyroid cancer	0.00146	0.0114	CbGpPWpGaD
Fulvestrant—Influenza—Vandetanib—thyroid cancer	0.00139	0.0112	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00135	0.0106	CbGpPWpGaD
Fulvestrant—ESRRA—lymph node—thyroid cancer	0.00128	0.0488	CbGeAlD
Fulvestrant—Infestation—Vandetanib—thyroid cancer	0.00124	0.00995	CcSEcCtD
Fulvestrant—Infestation NOS—Vandetanib—thyroid cancer	0.00124	0.00995	CcSEcCtD
Fulvestrant—ESR2—thyroid gland—thyroid cancer	0.00124	0.0471	CbGeAlD
Fulvestrant—Depression—Vandetanib—thyroid cancer	0.00124	0.00992	CcSEcCtD
Fulvestrant—ESR2—Nuclear Receptors—RXRA—thyroid cancer	0.00124	0.00965	CbGpPWpGaD
Fulvestrant—ESRRA—Nuclear Receptors—PPARG—thyroid cancer	0.00123	0.00957	CbGpPWpGaD
Fulvestrant—NR1H4—RXR and RAR heterodimerization with other nuclear receptor—PPARG—thyroid cancer	0.00121	0.00947	CbGpPWpGaD
Fulvestrant—Hepatic failure—Sorafenib—thyroid cancer	0.00121	0.00969	CcSEcCtD
Fulvestrant—Urinary tract infection—Vandetanib—thyroid cancer	0.00121	0.00967	CcSEcCtD
Fulvestrant—Leukorrhea—Epirubicin—thyroid cancer	0.00118	0.00946	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00117	0.00941	CcSEcCtD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00116	0.00905	CbGpPWpGaD
Fulvestrant—NR1H4—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00112	0.00875	CbGpPWpGaD
Fulvestrant—Haemoglobin—Vandetanib—thyroid cancer	0.00112	0.00898	CcSEcCtD
Fulvestrant—Haemorrhage—Vandetanib—thyroid cancer	0.00111	0.00893	CcSEcCtD
Fulvestrant—ESR2—head—thyroid cancer	0.0011	0.0418	CbGeAlD
Fulvestrant—Embolism venous—Epirubicin—thyroid cancer	0.0011	0.00879	CcSEcCtD
Fulvestrant—Vaginal moniliasis—Epirubicin—thyroid cancer	0.0011	0.00879	CcSEcCtD
Fulvestrant—Leukorrhea—Doxorubicin—thyroid cancer	0.00109	0.00875	CcSEcCtD
Fulvestrant—Pain in extremity—Sorafenib—thyroid cancer	0.00109	0.00871	CcSEcCtD
Fulvestrant—Vulvovaginal candidiasis—Epirubicin—thyroid cancer	0.00105	0.00843	CcSEcCtD
Fulvestrant—Vaginal moniliasis—Doxorubicin—thyroid cancer	0.00101	0.00813	CcSEcCtD
Fulvestrant—Embolism venous—Doxorubicin—thyroid cancer	0.00101	0.00813	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00101	0.00789	CbGpPWpGaD
Fulvestrant—Vulvovaginal mycotic infection—Epirubicin—thyroid cancer	0.00101	0.00811	CcSEcCtD
Fulvestrant—Angiopathy—Vandetanib—thyroid cancer	0.00101	0.00811	CcSEcCtD
Fulvestrant—NR1H4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000985	0.00769	CbGpPWpGaD
Fulvestrant—Breast disorder—Sorafenib—thyroid cancer	0.000981	0.00787	CcSEcCtD
Fulvestrant—NR1H4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00098	0.00764	CbGpPWpGaD
Fulvestrant—ESR2—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.000977	0.00762	CbGpPWpGaD
Fulvestrant—Vulvovaginal candidiasis—Doxorubicin—thyroid cancer	0.000973	0.0078	CcSEcCtD
Fulvestrant—Malnutrition—Vandetanib—thyroid cancer	0.000969	0.00778	CcSEcCtD
Fulvestrant—ESRRA—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000969	0.00756	CbGpPWpGaD
Fulvestrant—EPHX2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000969	0.00756	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00094	0.00734	CbGpPWpGaD
Fulvestrant—Vulvovaginal mycotic infection—Doxorubicin—thyroid cancer	0.000935	0.00751	CcSEcCtD
Fulvestrant—Vaginal discharge—Epirubicin—thyroid cancer	0.000909	0.00729	CcSEcCtD
Fulvestrant—Pelvic pain—Epirubicin—thyroid cancer	0.000909	0.00729	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000863	0.00674	CbGpPWpGaD
Fulvestrant—ESR1—thyroid gland—thyroid cancer	0.000849	0.0323	CbGeAlD
Fulvestrant—Cough—Vandetanib—thyroid cancer	0.000846	0.00679	CcSEcCtD
Fulvestrant—Vaginal discharge—Doxorubicin—thyroid cancer	0.000841	0.00675	CcSEcCtD
Fulvestrant—Pelvic pain—Doxorubicin—thyroid cancer	0.000841	0.00675	CcSEcCtD
Fulvestrant—Infestation NOS—Sorafenib—thyroid cancer	0.000837	0.00671	CcSEcCtD
Fulvestrant—Infestation—Sorafenib—thyroid cancer	0.000837	0.00671	CcSEcCtD
Fulvestrant—ESRRA—PPARA activates gene expression—RXRA—thyroid cancer	0.00083	0.00648	CbGpPWpGaD
Fulvestrant—Arthralgia—Vandetanib—thyroid cancer	0.000825	0.00662	CcSEcCtD
Fulvestrant—Chest pain—Vandetanib—thyroid cancer	0.000825	0.00662	CcSEcCtD
Fulvestrant—Anxiety—Vandetanib—thyroid cancer	0.000822	0.0066	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000819	0.00658	CcSEcCtD
Fulvestrant—ESRRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000812	0.00634	CbGpPWpGaD
Fulvestrant—NR1H4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000798	0.00623	CbGpPWpGaD
Fulvestrant—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000791	0.00635	CcSEcCtD
Fulvestrant—Infection—Vandetanib—thyroid cancer	0.000786	0.00631	CcSEcCtD
Fulvestrant—ESR2—Nuclear Receptors—PPARG—thyroid cancer	0.00078	0.00609	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Vandetanib—thyroid cancer	0.000776	0.00622	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000772	0.00602	CbGpPWpGaD
Fulvestrant—ESR2—lymph node—thyroid cancer	0.00077	0.0293	CbGeAlD
Fulvestrant—Skin disorder—Vandetanib—thyroid cancer	0.000768	0.00616	CcSEcCtD
Fulvestrant—Haemoglobin—Sorafenib—thyroid cancer	0.000755	0.00606	CcSEcCtD
Fulvestrant—ESR1—head—thyroid cancer	0.000753	0.0286	CbGeAlD
Fulvestrant—Haemorrhage—Sorafenib—thyroid cancer	0.000751	0.00603	CcSEcCtD
Fulvestrant—Vaginal haemorrhage—Epirubicin—thyroid cancer	0.000747	0.00599	CcSEcCtD
Fulvestrant—Connective tissue disorder—Sorafenib—thyroid cancer	0.000738	0.00592	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000721	0.00578	CcSEcCtD
Fulvestrant—Insomnia—Vandetanib—thyroid cancer	0.000715	0.00574	CcSEcCtD
Fulvestrant—Paraesthesia—Vandetanib—thyroid cancer	0.00071	0.0057	CcSEcCtD
Fulvestrant—NR1H4—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000708	0.00553	CbGpPWpGaD
Fulvestrant—Dyspnoea—Vandetanib—thyroid cancer	0.000705	0.00566	CcSEcCtD
Fulvestrant—Dyspepsia—Vandetanib—thyroid cancer	0.000696	0.00559	CcSEcCtD
Fulvestrant—Vaginal haemorrhage—Doxorubicin—thyroid cancer	0.000691	0.00554	CcSEcCtD
Fulvestrant—Decreased appetite—Vandetanib—thyroid cancer	0.000688	0.00552	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000683	0.00548	CcSEcCtD
Fulvestrant—Fatigue—Vandetanib—thyroid cancer	0.000682	0.00547	CcSEcCtD
Fulvestrant—Angiopathy—Sorafenib—thyroid cancer	0.000681	0.00547	CcSEcCtD
Fulvestrant—Immune system disorder—Sorafenib—thyroid cancer	0.000678	0.00544	CcSEcCtD
Fulvestrant—Injection site pain—Epirubicin—thyroid cancer	0.000677	0.00543	CcSEcCtD
Fulvestrant—Constipation—Vandetanib—thyroid cancer	0.000676	0.00543	CcSEcCtD
Fulvestrant—Pain—Vandetanib—thyroid cancer	0.000676	0.00543	CcSEcCtD
Fulvestrant—ESRRA—Organelle biogenesis and maintenance—RXRA—thyroid cancer	0.000665	0.00519	CbGpPWpGaD
Fulvestrant—Malnutrition—Sorafenib—thyroid cancer	0.000654	0.00525	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000647	0.00519	CcSEcCtD
Fulvestrant—NR1H4—Orphan transporters—RXRA—thyroid cancer	0.000634	0.00495	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000631	0.00492	CbGpPWpGaD
Fulvestrant—Vasodilation procedure—Epirubicin—thyroid cancer	0.000629	0.00505	CcSEcCtD
Fulvestrant—Vasodilation—Epirubicin—thyroid cancer	0.000629	0.00505	CcSEcCtD
Fulvestrant—Injection site pain—Doxorubicin—thyroid cancer	0.000626	0.00503	CcSEcCtD
Fulvestrant—Body temperature increased—Vandetanib—thyroid cancer	0.000625	0.00502	CcSEcCtD
Fulvestrant—Abdominal pain—Vandetanib—thyroid cancer	0.000625	0.00502	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000625	0.00487	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—THRB—thyroid cancer	0.000624	0.00487	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptors—RXRA—thyroid cancer	0.000623	0.00486	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—CDK1—thyroid cancer	0.00062	0.00484	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000617	0.00481	CbGpPWpGaD
Fulvestrant—ESR2—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000617	0.00481	CbGpPWpGaD
Fulvestrant—NR1H4—PPARA activates gene expression—RXRA—thyroid cancer	0.000606	0.00473	CbGpPWpGaD
Fulvestrant—Anaemia—Sorafenib—thyroid cancer	0.000604	0.00485	CcSEcCtD
Fulvestrant—Cough increased—Epirubicin—thyroid cancer	0.000604	0.00484	CcSEcCtD
Fulvestrant—Angioedema—Sorafenib—thyroid cancer	0.000597	0.00479	CcSEcCtD
Fulvestrant—NR1H4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000594	0.00463	CbGpPWpGaD
Fulvestrant—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000591	0.00461	CbGpPWpGaD
Fulvestrant—Leukopenia—Sorafenib—thyroid cancer	0.000585	0.0047	CcSEcCtD
Fulvestrant—Blood bilirubin increased—Epirubicin—thyroid cancer	0.000584	0.00469	CcSEcCtD
Fulvestrant—Vasodilation procedure—Doxorubicin—thyroid cancer	0.000582	0.00467	CcSEcCtD
Fulvestrant—Vasodilation—Doxorubicin—thyroid cancer	0.000582	0.00467	CcSEcCtD
Fulvestrant—Bone pain—Epirubicin—thyroid cancer	0.000577	0.00463	CcSEcCtD
Fulvestrant—ESR1—Estrogen signaling pathway—BRAF—thyroid cancer	0.000573	0.00447	CbGpPWpGaD
Fulvestrant—Cough—Sorafenib—thyroid cancer	0.000571	0.00458	CcSEcCtD
Fulvestrant—Inflammation—Epirubicin—thyroid cancer	0.00057	0.00457	CcSEcCtD
Fulvestrant—Asthenia—Vandetanib—thyroid cancer	0.000568	0.00455	CcSEcCtD
Fulvestrant—Pruritus—Vandetanib—thyroid cancer	0.00056	0.00449	CcSEcCtD
Fulvestrant—ESRRA—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.00056	0.00437	CbGpPWpGaD
Fulvestrant—Musculoskeletal pain—Epirubicin—thyroid cancer	0.000559	0.00449	CcSEcCtD
Fulvestrant—Cough increased—Doxorubicin—thyroid cancer	0.000559	0.00448	CcSEcCtD
Fulvestrant—Arthralgia—Sorafenib—thyroid cancer	0.000557	0.00447	CcSEcCtD
Fulvestrant—Myalgia—Sorafenib—thyroid cancer	0.000557	0.00447	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000553	0.00444	CcSEcCtD
Fulvestrant—Injection site reaction—Epirubicin—thyroid cancer	0.000549	0.00441	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000549	0.00429	CbGpPWpGaD
Fulvestrant—Diarrhoea—Vandetanib—thyroid cancer	0.000541	0.00434	CcSEcCtD
Fulvestrant—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.000541	0.00434	CcSEcCtD
Fulvestrant—Bone pain—Doxorubicin—thyroid cancer	0.000534	0.00428	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—MINPP1—thyroid cancer	0.000533	0.00416	CbGpPWpGaD
Fulvestrant—Infection—Sorafenib—thyroid cancer	0.00053	0.00425	CcSEcCtD
Fulvestrant—ESR1—Nuclear signaling by ERBB4—NRG1—thyroid cancer	0.000528	0.00412	CbGpPWpGaD
Fulvestrant—ESR1—lymph node—thyroid cancer	0.000528	0.0201	CbGeAlD
Fulvestrant—Inflammation—Doxorubicin—thyroid cancer	0.000527	0.00423	CcSEcCtD
Fulvestrant—ESRRA—PPARA activates gene expression—PPARG—thyroid cancer	0.000524	0.00409	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Sorafenib—thyroid cancer	0.000523	0.0042	CcSEcCtD
Fulvestrant—Dizziness—Vandetanib—thyroid cancer	0.000523	0.0042	CcSEcCtD
Fulvestrant—Skin disorder—Sorafenib—thyroid cancer	0.000518	0.00416	CcSEcCtD
Fulvestrant—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.000518	0.00415	CcSEcCtD
Fulvestrant—ESRRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000513	0.004	CbGpPWpGaD
Fulvestrant—Anorexia—Sorafenib—thyroid cancer	0.000509	0.00408	CcSEcCtD
Fulvestrant—Injection site reaction—Doxorubicin—thyroid cancer	0.000508	0.00408	CcSEcCtD
Fulvestrant—Vomiting—Vandetanib—thyroid cancer	0.000503	0.00404	CcSEcCtD
Fulvestrant—Rash—Vandetanib—thyroid cancer	0.000499	0.004	CcSEcCtD
Fulvestrant—Dermatitis—Vandetanib—thyroid cancer	0.000498	0.004	CcSEcCtD
Fulvestrant—Headache—Vandetanib—thyroid cancer	0.000496	0.00398	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000494	0.00385	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.000493	0.00384	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000486	0.0039	CcSEcCtD
Fulvestrant—Dyspnoea—Sorafenib—thyroid cancer	0.000476	0.00382	CcSEcCtD
Fulvestrant—Nausea—Vandetanib—thyroid cancer	0.00047	0.00377	CcSEcCtD
Fulvestrant—Dyspepsia—Sorafenib—thyroid cancer	0.00047	0.00377	CcSEcCtD
Fulvestrant—Decreased appetite—Sorafenib—thyroid cancer	0.000464	0.00372	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000461	0.0037	CcSEcCtD
Fulvestrant—Fatigue—Sorafenib—thyroid cancer	0.00046	0.00369	CcSEcCtD
Fulvestrant—Constipation—Sorafenib—thyroid cancer	0.000456	0.00366	CcSEcCtD
Fulvestrant—Pain—Sorafenib—thyroid cancer	0.000456	0.00366	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—THRB—thyroid cancer	0.000456	0.00356	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—NDUFA13—thyroid cancer	0.000453	0.00354	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000451	0.00352	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—NRAS—thyroid cancer	0.000449	0.00351	CbGpPWpGaD
Fulvestrant—Hepatic failure—Epirubicin—thyroid cancer	0.000446	0.00358	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000436	0.0035	CcSEcCtD
Fulvestrant—Hot flush—Epirubicin—thyroid cancer	0.000429	0.00344	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—MINPP1—thyroid cancer	0.000426	0.00333	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CHST14—thyroid cancer	0.000426	0.00333	CbGpPWpGaD
Fulvestrant—Menopausal symptoms—Epirubicin—thyroid cancer	0.000425	0.00341	CcSEcCtD
Fulvestrant—NR1H4—Biological oxidations—RXRA—thyroid cancer	0.000424	0.00331	CbGpPWpGaD
Fulvestrant—Urticaria—Sorafenib—thyroid cancer	0.000424	0.0034	CcSEcCtD
Fulvestrant—Abdominal pain—Sorafenib—thyroid cancer	0.000422	0.00338	CcSEcCtD
Fulvestrant—Body temperature increased—Sorafenib—thyroid cancer	0.000422	0.00338	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—TRIM33—thyroid cancer	0.000416	0.00324	CbGpPWpGaD
Fulvestrant—Hepatic failure—Doxorubicin—thyroid cancer	0.000413	0.00331	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—CDK1—thyroid cancer	0.000412	0.00321	CbGpPWpGaD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000409	0.00319	CbGpPWpGaD
Fulvestrant—Pain in extremity—Epirubicin—thyroid cancer	0.000401	0.00322	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—THRB—thyroid cancer	0.000397	0.0031	CbGpPWpGaD
Fulvestrant—Hot flush—Doxorubicin—thyroid cancer	0.000397	0.00318	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—MEN1—thyroid cancer	0.000396	0.00309	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptors—PPARG—thyroid cancer	0.000394	0.00307	CbGpPWpGaD
Fulvestrant—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000393	0.00316	CcSEcCtD
Fulvestrant—Hypersensitivity—Sorafenib—thyroid cancer	0.000393	0.00315	CcSEcCtD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—KRAS—thyroid cancer	0.000387	0.00302	CbGpPWpGaD
Fulvestrant—NR1H4—PPARA activates gene expression—PPARG—thyroid cancer	0.000383	0.00299	CbGpPWpGaD
Fulvestrant—Asthenia—Sorafenib—thyroid cancer	0.000383	0.00307	CcSEcCtD
Fulvestrant—Pruritus—Sorafenib—thyroid cancer	0.000378	0.00303	CcSEcCtD
Fulvestrant—NR1H4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000375	0.00292	CbGpPWpGaD
Fulvestrant—Pain in extremity—Doxorubicin—thyroid cancer	0.000371	0.00298	CcSEcCtD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—CCND1—thyroid cancer	0.000366	0.00285	CbGpPWpGaD
Fulvestrant—Diarrhoea—Sorafenib—thyroid cancer	0.000365	0.00293	CcSEcCtD
Fulvestrant—Breast disorder—Epirubicin—thyroid cancer	0.000363	0.00291	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—NDUFA13—thyroid cancer	0.000363	0.00283	CbGpPWpGaD
Fulvestrant—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000354	0.00276	CbGpPWpGaD
Fulvestrant—ESRRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000353	0.00276	CbGpPWpGaD
Fulvestrant—Dizziness—Sorafenib—thyroid cancer	0.000353	0.00283	CcSEcCtD
Fulvestrant—Influenza—Epirubicin—thyroid cancer	0.000347	0.00278	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—HPGD—thyroid cancer	0.000344	0.00268	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CHST14—thyroid cancer	0.000341	0.00266	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.00034	0.00265	CbGpPWpGaD
Fulvestrant—Vomiting—Sorafenib—thyroid cancer	0.000339	0.00272	CcSEcCtD
Fulvestrant—Rash—Sorafenib—thyroid cancer	0.000336	0.0027	CcSEcCtD
Fulvestrant—Dermatitis—Sorafenib—thyroid cancer	0.000336	0.0027	CcSEcCtD
Fulvestrant—Breast disorder—Doxorubicin—thyroid cancer	0.000335	0.00269	CcSEcCtD
Fulvestrant—Headache—Sorafenib—thyroid cancer	0.000334	0.00268	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—thyroid cancer	0.000331	0.00258	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—HRAS—thyroid cancer	0.000329	0.00257	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.000329	0.00256	CbGpPWpGaD
Fulvestrant—Influenza—Doxorubicin—thyroid cancer	0.000321	0.00257	CcSEcCtD
Fulvestrant—Nausea—Sorafenib—thyroid cancer	0.000317	0.00254	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—MINPP1—thyroid cancer	0.000312	0.00243	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000311	0.00243	CbGpPWpGaD
Fulvestrant—Infestation—Epirubicin—thyroid cancer	0.000309	0.00248	CcSEcCtD
Fulvestrant—Infestation NOS—Epirubicin—thyroid cancer	0.000309	0.00248	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—TERT—thyroid cancer	0.000304	0.00237	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—TRIM33—thyroid cancer	0.000304	0.00237	CbGpPWpGaD
Fulvestrant—Urinary tract infection—Epirubicin—thyroid cancer	0.000301	0.00241	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—THRB—thyroid cancer	0.0003	0.00234	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000297	0.00231	CbGpPWpGaD
Fulvestrant—Sweating—Epirubicin—thyroid cancer	0.000296	0.00238	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000292	0.00235	CcSEcCtD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—AKT1—thyroid cancer	0.00029	0.00227	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—MEN1—thyroid cancer	0.00029	0.00226	CbGpPWpGaD
Fulvestrant—Infestation—Doxorubicin—thyroid cancer	0.000286	0.0023	CcSEcCtD
Fulvestrant—Infestation NOS—Doxorubicin—thyroid cancer	0.000286	0.0023	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—HIF1A—thyroid cancer	0.000284	0.00222	CbGpPWpGaD
Fulvestrant—Haemoglobin—Epirubicin—thyroid cancer	0.000279	0.00224	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000279	0.00218	CbGpPWpGaD
Fulvestrant—Urinary tract infection—Doxorubicin—thyroid cancer	0.000278	0.00223	CcSEcCtD
Fulvestrant—Haemorrhage—Epirubicin—thyroid cancer	0.000278	0.00223	CcSEcCtD
Fulvestrant—Hepatitis—Epirubicin—thyroid cancer	0.000278	0.00223	CcSEcCtD
Fulvestrant—ESR1—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000277	0.00216	CbGpPWpGaD
Fulvestrant—Pharyngitis—Epirubicin—thyroid cancer	0.000275	0.00221	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—HPGD—thyroid cancer	0.000275	0.00214	CbGpPWpGaD
Fulvestrant—Sweating—Doxorubicin—thyroid cancer	0.000274	0.0022	CcSEcCtD
Fulvestrant—Oedema peripheral—Epirubicin—thyroid cancer	0.000273	0.00219	CcSEcCtD
Fulvestrant—Connective tissue disorder—Epirubicin—thyroid cancer	0.000273	0.00219	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000271	0.00217	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000266	0.00207	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—RXRA—thyroid cancer	0.000265	0.00207	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—NDUFA13—thyroid cancer	0.000265	0.00207	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—TRIM33—thyroid cancer	0.000264	0.00206	CbGpPWpGaD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000258	0.00202	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—CCND1—thyroid cancer	0.000258	0.00201	CbGpPWpGaD
Fulvestrant—Haemoglobin—Doxorubicin—thyroid cancer	0.000258	0.00207	CcSEcCtD
Fulvestrant—Hepatitis—Doxorubicin—thyroid cancer	0.000257	0.00206	CcSEcCtD
Fulvestrant—Haemorrhage—Doxorubicin—thyroid cancer	0.000257	0.00206	CcSEcCtD
Fulvestrant—Pharyngitis—Doxorubicin—thyroid cancer	0.000255	0.00205	CcSEcCtD
Fulvestrant—Oedema peripheral—Doxorubicin—thyroid cancer	0.000253	0.00203	CcSEcCtD
Fulvestrant—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000252	0.00202	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—MEN1—thyroid cancer	0.000252	0.00197	CbGpPWpGaD
Fulvestrant—Angiopathy—Epirubicin—thyroid cancer	0.000252	0.00202	CcSEcCtD
Fulvestrant—Immune system disorder—Epirubicin—thyroid cancer	0.000251	0.00201	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—CHST14—thyroid cancer	0.000249	0.00194	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—CP—thyroid cancer	0.000246	0.00192	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000246	0.00192	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000242	0.00189	CbGpPWpGaD
Fulvestrant—Malnutrition—Epirubicin—thyroid cancer	0.000242	0.00194	CcSEcCtD
Fulvestrant—Back pain—Epirubicin—thyroid cancer	0.000234	0.00188	CcSEcCtD
Fulvestrant—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000233	0.00182	CbGpPWpGaD
Fulvestrant—Angiopathy—Doxorubicin—thyroid cancer	0.000233	0.00187	CcSEcCtD
Fulvestrant—ESR1—Estrogen signaling pathway—AKT1—thyroid cancer	0.000232	0.00181	CbGpPWpGaD
Fulvestrant—Immune system disorder—Doxorubicin—thyroid cancer	0.000232	0.00186	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—NRAS—thyroid cancer	0.000227	0.00177	CbGpPWpGaD
Fulvestrant—Malnutrition—Doxorubicin—thyroid cancer	0.000224	0.00179	CcSEcCtD
Fulvestrant—Anaemia—Epirubicin—thyroid cancer	0.000223	0.00179	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000223	0.00174	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CDK1—thyroid cancer	0.000221	0.00173	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—THRB—thyroid cancer	0.00022	0.00171	CbGpPWpGaD
Fulvestrant—Vertigo—Epirubicin—thyroid cancer	0.000217	0.00174	CcSEcCtD
Fulvestrant—Leukopenia—Epirubicin—thyroid cancer	0.000216	0.00174	CcSEcCtD
Fulvestrant—Back pain—Doxorubicin—thyroid cancer	0.000216	0.00174	CcSEcCtD
Fulvestrant—Cough—Epirubicin—thyroid cancer	0.000211	0.00169	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000207	0.00161	CbGpPWpGaD
Fulvestrant—Anaemia—Doxorubicin—thyroid cancer	0.000207	0.00166	CcSEcCtD
Fulvestrant—Arthralgia—Epirubicin—thyroid cancer	0.000206	0.00165	CcSEcCtD
Fulvestrant—Myalgia—Epirubicin—thyroid cancer	0.000206	0.00165	CcSEcCtD
Fulvestrant—Chest pain—Epirubicin—thyroid cancer	0.000206	0.00165	CcSEcCtD
Fulvestrant—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000206	0.0016	CbGpPWpGaD
Fulvestrant—Anxiety—Epirubicin—thyroid cancer	0.000205	0.00164	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000204	0.00164	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—TPR—thyroid cancer	0.000203	0.00158	CbGpPWpGaD
Fulvestrant—Vertigo—Doxorubicin—thyroid cancer	0.000201	0.00161	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—HPGD—thyroid cancer	0.000201	0.00157	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—THRB—thyroid cancer	0.0002	0.00156	CbGpPWpGaD
Fulvestrant—Leukopenia—Doxorubicin—thyroid cancer	0.0002	0.00161	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—TPR—thyroid cancer	0.000197	0.00154	CbGpPWpGaD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000197	0.00154	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—CCND1—thyroid cancer	0.000197	0.00154	CbGpPWpGaD
Fulvestrant—Infection—Epirubicin—thyroid cancer	0.000196	0.00157	CcSEcCtD
Fulvestrant—Cough—Doxorubicin—thyroid cancer	0.000195	0.00157	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—KRAS—thyroid cancer	0.000195	0.00152	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PRKAR1A—thyroid cancer	0.000194	0.00152	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—RXRA—thyroid cancer	0.000194	0.00151	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Epirubicin—thyroid cancer	0.000193	0.00155	CcSEcCtD
Fulvestrant—Skin disorder—Epirubicin—thyroid cancer	0.000192	0.00154	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—THRB—thyroid cancer	0.000191	0.00149	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MEN1—thyroid cancer	0.000191	0.00149	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Epirubicin—thyroid cancer	0.000191	0.00153	CcSEcCtD
Fulvestrant—Arthralgia—Doxorubicin—thyroid cancer	0.00019	0.00153	CcSEcCtD
Fulvestrant—Myalgia—Doxorubicin—thyroid cancer	0.00019	0.00153	CcSEcCtD
Fulvestrant—Chest pain—Doxorubicin—thyroid cancer	0.00019	0.00153	CcSEcCtD
Fulvestrant—Anxiety—Doxorubicin—thyroid cancer	0.00019	0.00152	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000189	0.00152	CcSEcCtD
Fulvestrant—Anorexia—Epirubicin—thyroid cancer	0.000188	0.00151	CcSEcCtD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—thyroid cancer	0.000184	0.00144	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000184	0.00144	CbGpPWpGaD
Fulvestrant—Infection—Doxorubicin—thyroid cancer	0.000181	0.00145	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00018	0.00144	CcSEcCtD
Fulvestrant—Nervous system disorder—Doxorubicin—thyroid cancer	0.000179	0.00144	CcSEcCtD
Fulvestrant—Insomnia—Epirubicin—thyroid cancer	0.000178	0.00143	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000178	0.00139	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—NRG1—thyroid cancer	0.000178	0.00139	CbGpPWpGaD
Fulvestrant—Skin disorder—Doxorubicin—thyroid cancer	0.000177	0.00142	CcSEcCtD
Fulvestrant—Paraesthesia—Epirubicin—thyroid cancer	0.000177	0.00142	CcSEcCtD
Fulvestrant—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000176	0.00142	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000176	0.00137	CbGpPWpGaD
Fulvestrant—Dyspnoea—Epirubicin—thyroid cancer	0.000176	0.00141	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—CCND1—thyroid cancer	0.000176	0.00137	CbGpPWpGaD
Fulvestrant—Anorexia—Doxorubicin—thyroid cancer	0.000174	0.0014	CcSEcCtD
Fulvestrant—Dyspepsia—Epirubicin—thyroid cancer	0.000174	0.00139	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—CCND1—thyroid cancer	0.000172	0.00134	CbGpPWpGaD
Fulvestrant—Decreased appetite—Epirubicin—thyroid cancer	0.000171	0.00138	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000171	0.00134	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00017	0.00137	CcSEcCtD
Fulvestrant—Fatigue—Epirubicin—thyroid cancer	0.00017	0.00136	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—RXRA—thyroid cancer	0.000169	0.00132	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000169	0.00132	CbGpPWpGaD
Fulvestrant—Pain—Epirubicin—thyroid cancer	0.000169	0.00135	CcSEcCtD
Fulvestrant—Constipation—Epirubicin—thyroid cancer	0.000169	0.00135	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—PPARG—thyroid cancer	0.000167	0.00131	CbGpPWpGaD
Fulvestrant—ESR1—LKB1 signaling events—TP53—thyroid cancer	0.000167	0.0013	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000166	0.00133	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—HRAS—thyroid cancer	0.000166	0.00129	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—PTEN—thyroid cancer	0.000166	0.00129	CbGpPWpGaD
Fulvestrant—Insomnia—Doxorubicin—thyroid cancer	0.000165	0.00132	CcSEcCtD
Fulvestrant—Paraesthesia—Doxorubicin—thyroid cancer	0.000164	0.00131	CcSEcCtD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000163	0.00127	CbGpPWpGaD
Fulvestrant—Dyspnoea—Doxorubicin—thyroid cancer	0.000163	0.00131	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—CCND1—thyroid cancer	0.000162	0.00127	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000161	0.00129	CcSEcCtD
Fulvestrant—Dyspepsia—Doxorubicin—thyroid cancer	0.000161	0.00129	CcSEcCtD
Fulvestrant—Decreased appetite—Doxorubicin—thyroid cancer	0.000159	0.00127	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—TPR—thyroid cancer	0.000158	0.00123	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000158	0.00126	CcSEcCtD
Fulvestrant—Fatigue—Doxorubicin—thyroid cancer	0.000157	0.00126	CcSEcCtD
Fulvestrant—Urticaria—Epirubicin—thyroid cancer	0.000157	0.00126	CcSEcCtD
Fulvestrant—Pain—Doxorubicin—thyroid cancer	0.000156	0.00125	CcSEcCtD
Fulvestrant—Constipation—Doxorubicin—thyroid cancer	0.000156	0.00125	CcSEcCtD
Fulvestrant—Body temperature increased—Epirubicin—thyroid cancer	0.000156	0.00125	CcSEcCtD
Fulvestrant—Abdominal pain—Epirubicin—thyroid cancer	0.000156	0.00125	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—PRKAR1A—thyroid cancer	0.000155	0.00121	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000155	0.00121	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000152	0.00119	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000151	0.00118	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000149	0.0012	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—TPR—thyroid cancer	0.000148	0.00116	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—SLC5A5—thyroid cancer	0.000148	0.00115	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000147	0.00115	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—AKT1—thyroid cancer	0.000146	0.00114	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Epirubicin—thyroid cancer	0.000145	0.00117	CcSEcCtD
Fulvestrant—Urticaria—Doxorubicin—thyroid cancer	0.000145	0.00116	CcSEcCtD
Fulvestrant—Abdominal pain—Doxorubicin—thyroid cancer	0.000144	0.00116	CcSEcCtD
Fulvestrant—Body temperature increased—Doxorubicin—thyroid cancer	0.000144	0.00116	CcSEcCtD
Fulvestrant—Asthenia—Epirubicin—thyroid cancer	0.000141	0.00114	CcSEcCtD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000141	0.0011	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000141	0.0011	CbGpPWpGaD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00014	0.00109	CbGpPWpGaD
Fulvestrant—Pruritus—Epirubicin—thyroid cancer	0.00014	0.00112	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—MEN1—thyroid cancer	0.000139	0.00109	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000138	0.00108	CbGpPWpGaD
Fulvestrant—Diarrhoea—Epirubicin—thyroid cancer	0.000135	0.00108	CcSEcCtD
Fulvestrant—Hypersensitivity—Doxorubicin—thyroid cancer	0.000134	0.00108	CcSEcCtD
Fulvestrant—ESR1—Gene Expression—TRIM33—thyroid cancer	0.000133	0.00104	CbGpPWpGaD
Fulvestrant—Asthenia—Doxorubicin—thyroid cancer	0.000131	0.00105	CcSEcCtD
Fulvestrant—Dizziness—Epirubicin—thyroid cancer	0.00013	0.00105	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—TPR—thyroid cancer	0.000129	0.00101	CbGpPWpGaD
Fulvestrant—Pruritus—Doxorubicin—thyroid cancer	0.000129	0.00104	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—RXRA—thyroid cancer	0.000128	0.000996	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—MEN1—thyroid cancer	0.000127	0.000992	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000127	0.000992	CbGpPWpGaD
Fulvestrant—Vomiting—Epirubicin—thyroid cancer	0.000125	0.00101	CcSEcCtD
Fulvestrant—Diarrhoea—Doxorubicin—thyroid cancer	0.000125	0.001	CcSEcCtD
Fulvestrant—Rash—Epirubicin—thyroid cancer	0.000124	0.000998	CcSEcCtD
Fulvestrant—Dermatitis—Epirubicin—thyroid cancer	0.000124	0.000997	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—RXRA—thyroid cancer	0.000124	0.000969	CbGpPWpGaD
Fulvestrant—Headache—Epirubicin—thyroid cancer	0.000124	0.000991	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—PPARG—thyroid cancer	0.000122	0.000955	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MEN1—thyroid cancer	0.000121	0.000948	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000121	0.000942	CbGpPWpGaD
Fulvestrant—Dizziness—Doxorubicin—thyroid cancer	0.000121	0.000968	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—SLC5A5—thyroid cancer	0.000118	0.000922	CbGpPWpGaD
Fulvestrant—Nausea—Epirubicin—thyroid cancer	0.000117	0.00094	CcSEcCtD
Fulvestrant—Vomiting—Doxorubicin—thyroid cancer	0.000116	0.000931	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—TPR—thyroid cancer	0.000115	0.0009	CbGpPWpGaD
Fulvestrant—Rash—Doxorubicin—thyroid cancer	0.000115	0.000923	CcSEcCtD
Fulvestrant—Dermatitis—Doxorubicin—thyroid cancer	0.000115	0.000922	CcSEcCtD
Fulvestrant—Headache—Doxorubicin—thyroid cancer	0.000114	0.000917	CcSEcCtD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000114	0.000892	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PRKAR1A—thyroid cancer	0.000113	0.000885	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—thyroid cancer	0.000113	0.000882	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000113	0.000882	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000111	0.000864	CbGpPWpGaD
Fulvestrant—Nausea—Doxorubicin—thyroid cancer	0.000108	0.00087	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—PPARG—thyroid cancer	0.000107	0.000831	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000103	0.000802	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—HRAS—thyroid cancer	0.000102	0.000798	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.0001	0.000784	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—RXRA—thyroid cancer	9.92e-05	0.000775	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—AKT1—thyroid cancer	9.77e-05	0.000762	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	9.65e-05	0.000753	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—THRB—thyroid cancer	9.64e-05	0.000752	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—RXRA—thyroid cancer	9.33e-05	0.000728	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	9.28e-05	0.000724	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CALCB—thyroid cancer	9.15e-05	0.000714	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—AKT1—thyroid cancer	9.03e-05	0.000705	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	8.95e-05	0.000699	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PTEN—thyroid cancer	8.91e-05	0.000695	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TRIM33—thyroid cancer	8.67e-05	0.000677	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—SLC5A5—thyroid cancer	8.63e-05	0.000674	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—RXRA—thyroid cancer	8.51e-05	0.000664	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	8.51e-05	0.000664	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	8.49e-05	0.000663	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	8.48e-05	0.000662	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—RXRA—thyroid cancer	8.12e-05	0.000634	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.09e-05	0.000631	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PPARG—thyroid cancer	8.06e-05	0.000629	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—NRAS—thyroid cancer	7.95e-05	0.00062	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PPARG—thyroid cancer	7.84e-05	0.000612	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	7.69e-05	0.0006	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	7.42e-05	0.000579	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—RXRA—thyroid cancer	7.25e-05	0.000566	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.05e-05	0.00055	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	6.87e-05	0.000536	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—KRAS—thyroid cancer	6.84e-05	0.000534	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—TPR—thyroid cancer	6.51e-05	0.000508	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PPARG—thyroid cancer	6.27e-05	0.000489	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PTGS2—thyroid cancer	6.17e-05	0.000481	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MEN1—thyroid cancer	6.12e-05	0.000478	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	6.11e-05	0.000477	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—RXRA—thyroid cancer	6.07e-05	0.000474	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PPARG—thyroid cancer	5.89e-05	0.00046	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—HRAS—thyroid cancer	5.81e-05	0.000454	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TCF7L1—thyroid cancer	5.78e-05	0.000451	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.7e-05	0.000445	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PTEN—thyroid cancer	5.38e-05	0.00042	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—PPARG—thyroid cancer	5.37e-05	0.000419	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	5.16e-05	0.000403	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—AKT1—thyroid cancer	5.13e-05	0.000401	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PPARG—thyroid cancer	5.13e-05	0.0004	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.06e-05	0.000395	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PTGS2—thyroid cancer	4.93e-05	0.000385	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PPARG—thyroid cancer	4.58e-05	0.000357	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.46e-05	0.000348	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PTEN—thyroid cancer	4.3e-05	0.000335	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.28e-05	0.000334	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TSHR—thyroid cancer	4.23e-05	0.00033	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PRKAR1A—thyroid cancer	4.17e-05	0.000325	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—RXRA—thyroid cancer	4.1e-05	0.00032	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MEN1—thyroid cancer	3.98e-05	0.000311	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.79e-05	0.000296	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PTGS2—thyroid cancer	3.6e-05	0.000281	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTCH1—thyroid cancer	3.6e-05	0.000281	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CHST14—thyroid cancer	3.57e-05	0.000278	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SST—thyroid cancer	3.29e-05	0.000257	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—AKT1—thyroid cancer	3.19e-05	0.000249	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CALCA—thyroid cancer	3.17e-05	0.000247	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PTEN—thyroid cancer	3.14e-05	0.000245	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—AKT1—thyroid cancer	3.1e-05	0.000242	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HPGD—thyroid cancer	2.87e-05	0.000224	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDK1—thyroid cancer	2.87e-05	0.000224	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PPARG—thyroid cancer	2.59e-05	0.000202	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—AKT1—thyroid cancer	2.48e-05	0.000193	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—AKT1—thyroid cancer	2.33e-05	0.000182	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NRG1—thyroid cancer	2.3e-05	0.00018	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TERT—thyroid cancer	2.07e-05	0.000161	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—AKT1—thyroid cancer	2.03e-05	0.000158	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HIF1A—thyroid cancer	1.98e-05	0.000154	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—AKT1—thyroid cancer	1.81e-05	0.000141	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—TPR—thyroid cancer	1.65e-05	0.000129	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—BRAF—thyroid cancer	1.64e-05	0.000128	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.62e-05	0.000127	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.24e-05	9.64e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCND1—thyroid cancer	1.2e-05	9.33e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTEN—thyroid cancer	1.15e-05	9e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—RXRA—thyroid cancer	1.04e-05	8.1e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NRAS—thyroid cancer	1.03e-05	8.03e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—AKT1—thyroid cancer	1.02e-05	7.98e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KRAS—thyroid cancer	8.86e-06	6.91e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—thyroid cancer	7.87e-06	6.14e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HRAS—thyroid cancer	7.53e-06	5.88e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKT1—thyroid cancer	6.65e-06	5.19e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PPARG—thyroid cancer	6.55e-06	5.12e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.16e-06	4.02e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PTEN—thyroid cancer	4.5e-06	3.51e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AKT1—thyroid cancer	2.59e-06	2.02e-05	CbGpPWpGaD
